Seit 2010 arbeite ich an der Klinischen Abteilung für Infektionen und Tropenmedizin der Medizinischen Universität Wien. Als Facharzt für Innere Medizin leite ich dort die Interdisziplinäre Osteomyelitisambulanz und die Wundambulanz in der wir auch Studien zu state-of-the-art Wundtherapien durchführen.
Ein weiterer Forschungsschwerpunkt ist die korrekte Dosierung von Antiinfektiva in speziellen Patientengruppen wie Dialysepatienten oder Menschen die einer intensivmedizinischen Betreuung bedürfen.

Publikationen:

S2k Leitlinie “Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018”

1.Weiser, C. et al. Initial Electrical Frequency Predicts Survival And Neurological Outcome in Out Of Hospital Cardiac Arrest Patients with Pulseless Electrical Activity. Resuscitation (2018). doi:10.1016/j.resuscitation.2018.01.041
2.Vossen, M. G., Milacek, C. & Thalhammer, F. Empirical antimicrobial treatment in haemato-/oncological patients with neutropenic sepsis. ESMO Open 3, e000348 (2018).
3.Vossen, M. G. et al. Elimination of doripenem during dialysis and pharmacokinetic evaluation of post-hemodialytic dosing in intermittent renal replacement therapy. Antimicrob. Agents Chemother. (2018). doi:10.1128/AAC.02430-17
4.Tobudic, S. et al. Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-Year Experience at the General Hospital of Vienna. Clin Infect Dis (2018). doi:10.1093/cid/ciy279
5.Strassl, R. et al. Quantification of Torque Teno Virus Viremia as a Prospective Biomarker for Infectious Disease in Kidney Allograft Recipients. J. Infect. Dis. 218, 1191–1199 (2018).
6.Vossen, M. G. et al. Micafungin plasma levels are not affected by continuous renal replacement therapy – experience in critically ill patients. Antimicrob. Agents Chemother. AAC.02425-16 (2017). doi:10.1128/AAC.02425-16
7.Maier-Salamon, A. et al. Pharmacokinetics of flucloxacillin and its metabolites in patients with renal failure: Impact on liver toxicity. Int J Clin Pharmacol Ther 55, 701–711 (2017).
8.Knafl, D., Thalhammer, F. & Vossen, M. G. In-vitro release pharmacokinetics of amikacin, teicoplanin and polyhexanide in a platelet rich fibrin-layer (PRF)-a laboratory evaluation of a modern, autologous wound treatment. PLoS ONE 12, e0181090 (2017).
9.Jahn-Bassler, K., Bauer, W. M., Karlhofer, F., Vossen, M. G. & Stingl, G. Kombinierte Hoch-/Niedrig-Dosis-Therapie mit systemischen Glukokor-tikoiden bei schweren Verlaufsformen der Alopecia areata im Kindesalter. J Dtsch Dermatol Ges 15, 42–48 (2017).
10.Vossen, M., Mitteregger, D. & Steininger, C. Meningococcal pneumonia. Vaccine 34, 4364–4370 (2016).
11.Vossen, M. G. et al. Doripenem Treatment during Continuous Renal Replacement Therapy. Antimicrob. Agents Chemother. 60, 1687–1694 (2016).
12.Lemmerer, R. et al. Case report: spontaneous rupture of spleen in patient with Plasmodium ovale malaria. Wien. Klin. Wochenschr. (2015). doi:10.1007/s00508-015-0888-2
13.Vossen, M. G., Gattringer, K.-B., Jäger, W., Kraff, S. & Thalhammer, F. Single dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration. Antimicrob. Agents Chemother. (2014). doi:10.1128/AAC.01343-13
14.Vossen, D. M. G., Kielstein, J. T. & Thalhammer, F. Dosierung von Antiinfektiva bei CKD (5D). Nephrologe 9, 452–456 (2014).
15.Vossen, M. G. & Thalhammer, F. Pre-dialytic administration of aminoglycosides – case report and review of literature. GMS Infect Dis. 1, (2013).
16.Vossen, M. G. & Thalhammer, F. Effects of renal replacement therapy on antimicrobial therapy. Curr Clin Pharmacol 8, 39–45 (2013).
17.Vossen, M. G. et al. The First Case(s) of Botulism in Vienna in 21 Years: A Case Report. Case Rep Infect Dis 2012, 438989 (2012).
18.Vossen, M. G. et al. Gemella morbillorum bacteremia after anti-tumor necrosis factor alpha as acne inversa therapy. J. Clin. Microbiol. 50, 1109–1112 (2012).
19.Vossen, M. G., Pferschy, S., Chiba, P. & Noedl, H. The SYBR Green I malaria drug sensitivity assay: performance in low parasitemia samples. Am. J. Trop. Med. Hyg. 82, 398–401 (2010).
20.Thriemer, K. et al. Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial. J. Infect. Dis. 202, 392–398 (2010).
21.Vossen, M. G. et al. In vitro Interaktionsstudien mit Azithromycin und Dihydroartemisinin in Plasmodium falciparum Isolaten aus Bangladesh. Wiener klinische Wochenschrift 119, 71–75 (2007).
22.Thriemer, K. et al. In vitro interaction of dihydroartemisin and lumefantrine in clinical field isolates from Bangladesh. Wien. Klin. Wochenschr. 119, 67–70 (2007).

Menü schließen